HIF1A and diabetic kidney disease: As for the mechanism by which dapagliflozin could protect against DKD, previous studies illustrated its effect on inhibition of HIF-1α-mediated renal tubular cell metabolic disorders (28), amelioration of renal tubular ferroptosis (29), and alleviation of complement over-activation (30).